New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B: Comments

Hepatology

Volumn 41, Issue 6, 2005, Pages 1402-1406

  Berg, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; TELBIVUDINE; VIRUS DNA;

DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; LIVER BIOPSY; MONOTHERAPY; NOTE; PRIORITY JOURNAL; RELAPSE; REMISSION; SEROCONVERSION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 20044362586     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20743     Document Type: Note

References (27)

1. Lok ASF. Hepatitis B: progress in the last decade. Semin Liver Dis 2003; 23:1-4.
2. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10: 298-305.
3. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.
4. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
5. Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongasawat S, Cooksley G, et al. Peginterferon alfa-2a (40KD) (Pegasys) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. HEPATOLOGY 2004;40(Suppl 1):171A.
6. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005;142:240-250.
7. Richman D. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. HEPATOLOGY 2000;32:866-867.
8. Liaw YF. Results of lamivudine trials in Asia. J Hepatol 2003;39:(Suppl 1):S111-S115.
9. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. HEPATOLOGY 2003;33:1527-1532.
10. Marcellin P, Chang TT, Lim S, Sievert W, Tong M, Arterburn S, et al. Long-term efficacy and safety of adefovir (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients: increasing serologic, virologic and biochemical response over time. HEPATOLOGY 2004;40(Suppl 1):655A.
11. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. HEPATOLOGY 2003;37:748-755.
12. Chang TT, Shiffman M, Tong M, Marcellin P, Liaw Y-F, Luengrojanakul P, et al. Durability of HBeAg seroconversion after adefovir dipivoxil treatment for chronic hepatitis B. J Hepatol 2004;40(Suppl 1):126A.
13. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004;11:432-438.
14. Keefe EB, Dietrich DT, Han S-HB, Jacobson IM, Martin P, Schiff ER, Tobias H et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
15. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. HEPATOLOGY 2002;36:1408-1415.
16. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-109.
17. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-1758.
18. Shiffman M, Marcellin P, Jeffers L, Gordon S, Peters M, Rizzetto M, et al. HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B patients. J Hepatol 2004;40(Suppl 1):17A.
19. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. HEPATOLOGY 2002;37:1309-1319.
20. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
21. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. HEPATOLOGY 2004;40: 883-891.
22. Chang TT, Gish R, de Man R, Gadano A, Sollano J, Han KH, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside naive patients. HEPATOLOGY 2004;40(Suppl 1):192A.
23. Lai CL, Lim SG, Brown NA, Zouh XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg positive patients with chronic hepatitis B virus infection. HEPATOLOGY 2004;40:719-726.
24. van Bömmel F, Wünsche T, Mauss S, Reinke P, Bergk A, Schürmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. HEPATOLOGY 2004;40:1421-1425.
25. Fung SK, Lok ASF. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection. HEPATOLOGY 2004;40:790-792.
26. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. HEPATOLOGY 2002;36:186-194.
27. Janssen HLA, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. HEPATOLOGY 1999;30:238-243.